Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2014-001743-20-ES
EUCTR2014-001743-20-ES
Active, not recruiting
Not Applicable

A Multicentre, prospective, randomised clinical trial comparing the cost and efficacy of corifolitropina alfa vs Recombinant FSH and / or HP-hMG - Use of the corifolitropina alfa in oocyte donors

IVI Madrid0 sitesAugust 14, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsThe study is proposed to determine the level of compliance and pharmacoeconomic impact of three protocols for controlled ovarian stimulation in women participating in oocyte donation programTherapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
DrugsElonvaPuregonMenopur

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
The study is proposed to determine the level of compliance and pharmacoeconomic impact of three protocols for controlled ovarian stimulation in women participating in oocyte donation program
Sponsor
IVI Madrid
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 14, 2014
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
IVI Madrid

Eligibility Criteria

Inclusion Criteria

  • •Women aged 18\-35 years who meet the entry criteria for the IVI Donor Program and will be receiving stimulation with gonadotropins.
  • •\- Weight \<60 kg
  • •\- Women with at least 6 antral follicles per ovary
  • •\- Will to fit the protocol during the study period
  • •\- Woman who gives written consent to participate in Test
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 300
  • •F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • •\- Woman with a basal antral follicle count above 20 or below 6
  • •\- Women with comorbidities, in the judgment of the investigator, that may interfere with the treatment of ovarian stimulation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation - Recaltox-1
EUCTR2007-001166-33-DEniversitaetsklinikum Erlangen-Nuernberg
Active, not recruiting
Not Applicable
A study Protocol for patients with relapsed osteosarcomaHigh malignancy grade of osteosarcoma relapseMedDRA version: 14.1Level: PTClassification code 10031296Term: Osteosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2012-001010-42-ITITALIAN SARCOMA GROUP
Not yet recruiting
Phase 4
Multicentre, prospective, randomised clinical survey to evaluate early fusion rate after instrumented lumbar stabilization with either MectaLIF PEEK lumbar cage or MectaLIF TiPEEK lumbar cageDisorders that are treated with lumbar intervertebral body fusion, such as lumbar spondylolisthesis
JPRN-UMIN000027744INCREASE Co., Ltd.240
Not yet recruiting
Phase 4
A randomized, controlled, multicentre clinical study of Shengu Capsule in the treatment of postmenopausal osteoporosis (deficiency syndrome of liver and kidney)
ITMCTR2100004996Fujian Academy of Chinese Medical Sciences
Recruiting
Phase 1
A randomized, controlled, multicentre clinical study of optimizing Yantiao prescription in the treatment of septic shockSeptic shock
ITMCTR2100004495Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine